India, April 9 -- Shares of RemeGen Co., Ltd. gained around 10 percent in the Hong Kong trading on Wednesday after the Chinese biotechnology company revealed positive results from the Phase 3 clinical trial to assess the efficacy and safety of Telitacicept, also known as RC18, in patients with Generalized Myasthenia Gravis or gMG.
On the Hong Kong Stock Exchange, the stock traded up 9.6 percent to close at HK$25.950.
With the highest Myasthenia Gravis Activities of Daily Living or MG-ADL response rate among all drugs for gMG with phase 3 studies reported to date, Telitacicept will provide an important new treatment option for gMG, the company noted.
Myasthenia Gravis is an autoimmune disease that disrupts neuromuscular junction transmiss...